Assessment of the efficacy and safety of tocilizumab in patients over 80 years old with giant cell arteritis

Table 3 Adverse events and outcomes observed in patients once TCZ started for GCA

Adverse event	Months after TCZ introduction	Dose of GC at AE time	GC duration (months)	CTCAE grade	Treatment/evolution
Patient 1
Hypercholesterolemia	4	10 mg	4	2	No treatment, stable
Patient 2
Hypercholesterolemia	8	10 mg	8	3	Statin, improvement
Patient 3
Hypercholesterolemia	3	0	–	2	No treatment, stable
Patient 4
Pyelonephritis	5	10 mg	9	3	IV antibiotics-TCZ shifted 1 month later
Thrombopenia	2	15 mg	6	1 (75 G/l)	No treatment, stable
Patient 5
Bronchitis	9	6 mg	13	2	Oral antibiotics, healed
Neutropenia	7	8 mg	11	3 (900/mm³)	No treatment, stable
Hepatic cytolysis	7	8 mg	11	3 (5N)	Reduction TCZ to 4 mg/kg, correction of cytolysis
Patient 6
Septic shock^a	20	0	–	5	Death
Mesenteric infarction^a	20	0	–	5
Patient 7
Hypercholesterolemia	9	0	–	2	No treatment, stable

Values are numbers (%). TCZ, tocilizumab; AE, adverse events; IV, intravenous; G, giga; N, normal; GC, glucocorticoid; CTCAE, Common Toxicity Criteria for Adverse Events
^aOccurred post-surgery for a programmed cholecystectomy. TCZ was temporally stopped for 2 months

ISSN: 1478-6362